
VITA IMAGING
OperatingVita Imaging Inc.
Healthcare · San Jose, CA · Founded 2019
Cutting-edge cancer detection and diagnostic technology
Financials
FY2021–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round. Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Cap table
Share counts as of Dec 31, 2025| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Series A preferred stockpreferred(as of Dec 31, 2024) | 6,321,179 | 1 | 49.2% | $5.70Jul 2026 |
| Common stock | 6,520,359 | 1 | 50.8% | — |
| Total | 12,841,538 | 100% |
Shares outstanding over timein today's share terms
Changes in named holdersshares in today's terms · % of all shares at the time
- Thinh Tran748K (5.82%) Jul 2025 → 1.2M (9.37%) Jul 2026
Principal holders% as the filing states it, Jul 13, 2026
- Thinh Tran1,202,795 Series A Preferred Stock12.1%of votes
Sold to the crowd
- Reg CF · May 202363,308 shares at $5.70$360.9K· 582 investors
- Reg CF · Feb 202463,110 shares at $5.70$359.7K
- Reg CF · Aug 2024143,086 shares at $5.70$815.6K· 323 investors
- Reg CF · Jul 202558,001 shares at $5.70$330.6K· 238 investors
- Reg CF · Jul 2026801 Common Stock at $5.70$4.6K
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
3 people
Mr. Tran was the Founder, CEO, & Chairman of V-Silicon, a leader in the Smart TV market delivering best in class picture and audio quality. He was previously the Founder, Chairman, & CEO of Sigma Designs since its inception in 1982 which he built from a humble start-up a publicly traded NASDAQ company, at one point was valued at two billion dollars in 2007, before leaving in 2018. Thinh also has extensive experience raising capital, exceeding M&A transactions, and providing guidance to many start-ups. Prior to Sigma Designs, Mr. Tran was employed by Amdahl Corporation and Trilogy Systems Corporation. Thinh holds a B.S.E.E. from the University of Wisconsin & M.S.E.E. from Stanford University.

Ms. Wright is the Chief Financial Officer of Vita Imaging, Inc. She has over 30 years of experience in the financial industry, holding senior financial positions at multiple publicly traded and startup companies over a wide range of industries such as medical, telecommunications, device technology, digital arts, mobile devices, and internet technology. Before joining Vita Imaging, Dzung was Sr. Accounting Manager at Vivus, Inc. from 2013 to 2022 where she was Responsible for overseeing the corporate accounting team for a publicly traded pharmaceutical company. She has also held senior finance roles at Controlnet Inc., Foneweb Inc., and Microlambda Wireless Inc. She has a proven track record of success in leading and managing financial teams, and she has a deep understanding of financial reporting, analysis, and planning. Dzung is a graduate of San Jose State University and holds a Bachelor’s degree in Business Administration and Accounting.

Ms. Reade has 25+ years of executive leadership and consulting experience including: Executive Director, MCO Operations & MSO at Scripps Clinic & Green Hospital La Jolla; VP, Medical Management at HMO Pacificare, Healthcare/IT Consultant at Deloitte, TMI, Pharma & Medtech. Previously, she was the Founder and CEO of Ion Therapeutics, a medical device & biologics company where she successfully secured FDA device approval; served as CEO & Chief Administrative Officer (CAO) of College Medical Center (157 bed hospital); Site Director, Quest Clinical Research conducting Pivotal Studies; and Research Leader of UCSD & Schepens Institute/Harvard teams. Ms. Reade holds an MBA from Pace University and a Bachelor of Science Nursing (BSN) from the University of Tennessee Center for Health Sciences. She is an Advisor for Business and Academic Accelerator Programs (California Life Sciences Institute & Hult Global Business Challenge).
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 3 of 3 annual reports (FY2023–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 26 filings on EDGAR- Form C-WOct 2, 20260001804181-26-000005EDGAR
- Form C/AJul 13, 20260001804181-26-000003EDGAR
- Form CJul 10, 20260001804181-26-000002EDGAR
- Form C-ARJul 9, 20260001099910-26-000235EDGAR
- Form C-UFeb 5, 20260001804181-26-000001EDGAR
- Form C/ADec 12, 20250001804181-25-000004EDGAR
- Form C/AOct 16, 20250001804181-25-000003EDGAR
- Form CJul 23, 20250001665160-25-001320EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.